Munirah A. Alkathiri

Ms. Munirah A. Alkathiri

College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2020 in Molecules
Verified
Journal Article
Open access
PDF file
AAAli Aldalbahi
Ali Aldalbahi
STSeham Al Terary
Seham Al Terary
RARuba Almoghim
Ruba Almoghim
MAManal Ahmed Awad
Manal Ahmed Awad
NANoura S. Aldosari
Noura S. Aldosari
RARaghad Abdulrahman Alrashed
Raghad Abdulrahman Alrashed
Nanoparticles (NPs) have unique properties compared to their bulk counterparts, and they have potentials for various applications in many fields of life science. Green-synthesized NPs have garnered considerable interest due to their inherent features such as rapidity, eco-friendliness and cost-effectiveness. Zinc oxide nanoparticles (ZnO NPs) were synthesized using an aqueous extract of Kalanchoe blossfeldiana as a reducing agent. The resulting nanoparticles were characterized via X-ray diffraction (XRD), dynamic light scattering (DLS), UV-Vis spectroscopy, photoluminescence (PL), transmission electron microscopy (TEM), scanning electron microscopy (SEM) and energy-dispersive spectroscopy (EDS). The antimicrobial potential of the synthesized ZnO NPs against bacterial and fungal strains was examined by the disk diffusion method, and they showed a promising antibacterial and antifungal potential. The catalytic activity of the synthesized ZnO NPs in reducing methylene blue (MB) and eosin was studied via UV-Vis spectroscopy. The decolorization percentages of the MB and Eosin Y dyes were 84% and 94%, respectively, which indicate an efficient degradation of the ZnO NPs. In addition, the cytotoxic activity of the ZnO NPs on the HeLa cell line was evaluated via in vitro assay. The MTT assay results demonstrate a potent cytotoxic effect of the ZnO NPs against the HeLa cancer cell line.

1 February 2022 in Psychology Research and Behavior Management
Verified
Journal Article
Open access
PDF file
MAMunirah A. Alkathiri
Munirah A. Alkathiri
OAOmar Abdulrahman Almohammed
Omar Abdulrahman Almohammed
FAFaleh Alqahtani
Faleh Alqahtani
YAYazed AlRuthia
Yazed AlRuthia
Purpose: The coronavirus disease (COVID-19) outbreak combined with social distancing, isolation, and movement restrictions has had a profound impact on individuals’ physical and psychological well-being. The aim of this study was to examine the associations of depression and anxiety with feelings of stigma among patients in Saudi Arabia who have recovered from COVID-19. Materials and Methods: A cross-sectional survey was conducted between July and December 2020. Trained healthcare providers contacted and interviewed participants by phone. Depression, anxiety, and stigma were assessed using the Patient Health Questionnaire (PHQ-9), the Generalized Anxiety Disorder (GAD-7) questionnaire, and the Explanatory Model Interview Catalogue stigma scale (EMIC). Data on sociodemographic characteristics, comorbidities, and family history of mental illness were also collected. Multiple linear regression models were performed to explore factors associated with depression and anxiety. Results: A total of 174 adult participants (≥ 18 years old) who had recently recovered from COVID-19 were interviewed. The mean PHQ-9 and GAD-7 scores were 7.53 (± 5.04) and 3.77 (± 4.47), respectively. About 68% of the participants had at least mild depression (PHQ-9 score of 5– 9), whereas only 29.89% had at least mild anxiety (GAD-7 score of 5– 9) during their infections with COVID-19. Multiple linear regression showed that females were more vulnerable to depression and anxiety disorders than their male counterparts were (β=3.071 and β=1.86, respectively). Notably, participants’ stigma scores were significantly associated with higher scores on depression and anxiety. Conclusion: These findings highlight the negative consequences of COVID-19 infection on the mental health of recovered patients. Therefore, considerable attention from local and international health authorities is needed to improve the mental well-being of recovered COVID-19 patients.

LALamia A. Al-Zamel
Lamia A. Al-Zamel
SAShatha Althunayan
Shatha Althunayan
AAAfnan A. Al-Rasheed
Afnan A. Al-Rasheed
MAMunirah A. Alkathiri
Munirah A. Alkathiri
FAFaisal F Al-Amri
Faisal F Al-Amri
YAYazed AlRuthia
Yazed AlRuthia
Stigma is a negative feeling affecting many patients with various health conditions, especially the contagious ones such as COVID-19. The Explanatory Model Interview Catalogue (EMIC) is one of the valid and reliable stigma-measuring tools; however, it has not been translated and validated in Arabic. Therefore, the aim of this study was to translate and validate the EMIC in Arabic among a sample of Arabic-speaking adults who recently recovered from COVID-19 in Saudi Arabia. The 12 items of the EMIC scale were forward- and backward-translated and reviewed by all authors to check the face and content validity prior to approving the final version of the Arabic 12-item EMIC. A total of 174 participants aged ≥18 years who contracted COVID-19 and recovered as of 29 July 2020 were interviewed. The Cronbach’s alpha of the Arabic version of the 12-item EMIC was 0.79, indicating an acceptable level of internal consistency. Using principal component analysis with varimax rotation, two factors explained more than 60% of the variance of the translated EMIC scale. The mean EMIC score was 5.91, implying a low level of stigma among participants. Married participants (β = 2.93; 95%CI 0.88 to 4.98, p = 0.005) and those with a family history of mental illness (β = 2.38; 95%CI 0.29 to 4.46, p = 0.025) were more likely to have higher EMIC scores in comparison to their counterparts who were unmarried and had no family history of mental illness. On the contrary, older adults were less likely to have high EMIC scores (β = −0.11; 95%CI −0.21 to −0.01, p = 0.03). Future studies with larger samples of patients with COVID-19 and various health conditions should be conducted to examine the validity and reliability of the Arabic version of the EMIC among different patient populations and to unveil the factors that may play a role in patients’ feelings of stigmatization in this part of the world.

FAFaisal F Al-Amri
Faisal F Al-Amri
Aslam KhanAslam Khan
Aslam Khan
AAAbdulaziz O. Alshehri
Abdulaziz O. Alshehri
AAAhmed Assiri
Ahmed Assiri
Shahd KhanShahd Khan
Shahd Khan
FAFaleh Alqahtani
Faleh Alqahtani
The world is still in need of an effective therapy to treat coronavirus disease-19 (COVID-19). This cross-sectional study was conducted on COVID-19 survivors in Saudi Arabia to investigate the influence of a healthy diet on the recovery time from COVID-19. A questionnaire was developed to assess participants’ dietary habits, based on the 2015 Dutch food-based dietary guidelines. A total of 738 COVID-19 survivors participated in the study, of whom 237 (32.1%) were hospitalized for COVID-19 treatment while 501 (76.9%) were not hospitalized, and 320 (43.4%) were females and 418 (56.6%) were males. Overall, no significant difference was noted in healthy diet score between males and females; however, this score was significantly lower for Saudis compared to non-Saudis. Among the non-hospitalized patients, eating a more healthy diet was associated with a shorter duration of recovery (p < 0.05) and was significantly affected by gender (15.8 ± 9.3 male vs. 12.1 ± 8.9 female; p < 0.001) and marital status (12.1 ± 8.4 singles vs. 13.7 ± 9.3 married vs. 16.1 ± 11.8 divorced; p < 0.05). In contrast, no significant correlation was found with age or BMI. In this study, a more healthy diet was associated with a shorter duration of recovery from COVID-19. However, further studies are needed to thoroughly investigate the relationship between diet and recovery time from COVID-19.

1 January 2020
Verified
Open access
DADalal A. Alabdulkarim
Dalal A. Alabdulkarim
OAOmar Abdulrahman Almohammed
Omar Abdulrahman Almohammed
AAAmmari Maha A. Al Ammari
Ammari Maha A. Al Ammari
NANada S. Almaklafi
Nada S. Almaklafi
MAMunirah A. Alkathiri
Munirah A. Alkathiri
MAManal A. Aljohani
Manal A. Aljohani
Background Hospitalized elderly patients are at high risk of venous thromboembolism (VTE), and the appropriate use of thromboprophylaxis can significantly reduce the incidence of VTE in high-risk patients. We investigated the pattern of VTE prophylaxis administration among elderly medical patients and assessed its appropriateness based on the American College of Chest Physicians (ACCP) recommendations. Methods A cross-sectional single-center study was conducted between October 2019 and March 2020, including hospitalized (> 48 h), elderly (>= 60 years), medical patients, and excluding patients receiving anticoagulant for other reason, having contraindication to thromboprophylaxis, or had VTE diagnosed within 48 h. The Padua prediction score was used to determine the patients' risk for VTE, and thromboprophylaxis use was assessed against the ACCP recommendations. Results The study included 396 patients with an average age of 75.0 +/- 9.01 years, and most patients (71.7%) were classified as high risk for VTE development (Padua score = 4 points). Thromboprophylaxis use was inappropriate in 27.3% of patients, of whom 85.2% were ineligible but still received thromboprophylaxis. Patients who were classified as low risk of VTE were more likely to receive inappropriate thromboprophylaxis (AOR = 76.5, 95% CI: 16.1-363.2), whereas patients with acute infection or rheumatologic disorder were less likely to receive inappropriate thromboprophylaxis (AOR = 0.46, 95% CI: 0.22-0.96). Conclusions Although the use of thromboprophylaxis among high-risk elderly patients was reasonably adequate, a large proportion of low-risk patients were exposed to unnecessary risk through inappropriate overutilization of thromboprophylaxis. Thus, healthcare providers should accurately assess patients' risk before prescribing thromboprophylaxis to ensure patient safety.

11 June 2025 in Pharmacy
Verified
Journal Article
Open access
PDF file
TATamather Almandeel
Tamather Almandeel
MKMansoor Ahmed Khan
Mansoor Ahmed Khan
AAAshwag Algethami
Ashwag Algethami
MAMashael S. Alaboud
Mashael S. Alaboud
MAMunirah A. Alkathiri
Munirah A. Alkathiri
AAAbdullah Alotaibi
Abdullah Alotaibi
Background: Biosimilar versions of rituximab have similar safety and efficacy as the reference product across all indications based on the extrapolation principle. Our organization replaced intravenous (IV) rituximab (Mabthera) with IV rituximab (Truxima-Biosimilar) in 2021. Hence, our practice changed to providing first cycles of IV rituximab (Truxima-Biosimilar) instead of rituximab (Mabthera), and if the first cycle was completed without severe infusion-related reactions (IRRs), then subsequent cycles were given with subcutaneous (SC) rituximab as per institutional guidelines. However, the safety of this approach has not been evaluated. Methods: A retrospective study was conducted at the Princess Nourah Oncology Center in Saudi Arabia. The primary objective was to assess IRRs after using IV rituximab (Truxima-Biosimilar) in the first cycle followed by SC rituximab in subsequent cycles. Results: Of the 71 patients reviewed, 35 patients met the eligibility criteria. Only one (3%) patient developed an IRR. However, it was a Grade 1 IRR, as per CTCAE.V5, and the patient was able to complete the remaining IV infusion successfully. Hence, all patients transitioned from IV rituximab biosimilar to SC rituximab Mabthera. Conclusions: This real-world study demonstrates that transitioning from IV rituximab biosimilar to SC Mabthera is a well-tolerated and safe practice, confirming the extrapolation principle of biosimilars.